The tumor-suppressive microenvironment mediated by Tregs is a significant obstacle to successful immunotherapy, suggesting that depletion of Treg cells, like immune checkpoint blockade of CTLA-4 or PD1/PDL1, could be a potentially effective immunotherapy for ovarian cancer (46). This evidence concerns the gene CTLA4 and ovarian carcinoma.